Immunotherapy plus radiation aims to stop liver cancer recurrence

NCT ID NCT07186621

Recruiting now Disease control Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 3 trial tests whether combining radiotherapy with the immunotherapy drug sintilimab can better prevent liver cancer from coming back after surgery, compared to the standard TACE procedure. The study enrolls 286 adults with high-risk features like narrow surgical margins or microvascular invasion. Participants will receive either the combination therapy or TACE, and researchers will track cancer recurrence and survival over two years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sintilimab (an immunotherapy drug) and radiotherapy (targeted radiation)
What this could lead to: If successful, this combination could offer a more effective way to prevent liver cancer from coming back after surgery, potentially improving survival without the need for repeated procedures.
What could go wrong: This is a mid-stage trial, so results are not guaranteed. The experimental treatment may cause side effects like immune-related inflammation or radiation damage, and it may not prove better than the standard TACE approach.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA (HCC) IMMUNE CHECKPOINT INHIBITOR NARROW MARGIN RADIOTHERAPY, ADJUVANT TACE

Contacts and locations

Locations

Cancer Institute and Hospital, Chinese Academy of Medical Sciences
RECRUITING

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.